Alizapride

證據等級: L5

預測適應症: 0 個

Alizapride: Drug Repurposing Evaluation Report

One-Sentence Summary

Alizapride is a benzamide-derivative dopamine antagonist antiemetic (DrugBank ID: DB01425), not currently marketed in Taiwan. The TxGNN model has no predicted new indications for this drug at present, and the evidence pack contains 0 clinical trials and 0 publications to support any repurposing direction.

Quick Overview

Item	Content
Original Indication	Not available (no TFDA-approved indications on record)
Predicted New Indication	None — no TxGNN predictions available
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions or supporting studies)
Taiwan Market Status	✗ Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data is not available in the evidence pack. Based on known pharmacological information, Alizapride is a substituted benzamide that acts as a dopamine D₂ receptor antagonist. It is used in some countries (primarily in Europe) as an antiemetic for the management of nausea and vomiting, including chemotherapy-induced and postoperative nausea.

However, no TxGNN-predicted new indications were generated for Alizapride. The predicted_indications array is empty, meaning the graph neural network model did not identify any high-confidence repurposing candidates for this compound at the current data cutoff (2026-04-03).

Without a predicted indication, a mechanistic plausibility analysis cannot be performed. Further data enrichment — particularly the drug's MOA details from DrugBank and regulatory label information — may enable future prediction runs to yield actionable results.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Taiwan Market Information

Alizapride has no TFDA marketing authorizations in Taiwan. There are no registered licenses, product names, or approved dosage forms on record.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA package insert data, key warnings, contraindications, and drug–drug interaction data were all queried but returned no results for Alizapride. This is consistent with the drug not being marketed in Taiwan.

Data Gaps Summary

The following critical data gaps were identified in this evidence pack:

Gap ID	Category	Item	Severity	Impact	Remediation
DG001	Drug Level	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot proceed to S1 safety screening	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN-predicted indications exist for Alizapride, the drug is not marketed in Taiwan (0 authorizations), and critical safety data (warnings, contraindications) is entirely missing. There is insufficient evidence to support any repurposing evaluation at this time.

To proceed, the following is needed:

Resolve DG001 (Blocking): Obtain TFDA package insert warnings and contraindications, or source equivalent safety data from EMA/FDA databases since the drug is marketed in Europe
Resolve DG002 (High): Retrieve detailed MOA data from DrugBank API to enable mechanistic analysis
Re-run TxGNN prediction pipeline after enriching the drug's knowledge graph representation with MOA, target, and pathway data
Evaluate whether Alizapride's dopamine D₂ antagonist profile yields viable repurposing candidates in a subsequent prediction cycle
Consider sourcing regulatory and clinical data from EMA (European Medicines Agency), as Alizapride has market presence in select European countries
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.